Key result
A 48-year-old male developed an extremely rare angiosarcoma in a ligated native arteriovenous fistula on the background of immunosuppression following a renal transplant.
Case Report (n=1)
Angiosarcoma is a rare but important differential diagnosis for an evolving mass near the site of an AV fistula in immunosuppressed post-transplant patients.
Answers are grounded in this paper and cite their sources.
Angiosarcoma warrants consideration in evolving masses near ligated AV fistulas in immunosuppressed transplant patients; leaves open questions on incidence and surveillance.
BACKGROUND: Angiosarcomas comprise less than 1% of all sarcomas, arising from endothelial cells of blood or lymph vessels. Chronic immunosuppression increases the risk of many malignancies and an association between the development of angiosarcoma with an immunosuppressed state is established. A few cases have been reported of angiosarcomas arising in the post-renal transplant patient. Specifically, there have been six cases of an angiosarcoma arising in arteriovenous (AV) fistulae in this patient population. We describe a further case and review the relevant literature with specific emphasis on a possible mechanism for the development of angiosarcoma in the post-transplant patient. CASE PRESENTATION: We report the case of a 48-year-old male who developed an angiosarcoma in a ligated native AV fistula. The lesion arose on the background of immunosuppression following a successful ABO-incompatible renal transplant for chronic renal failure. CONCLUSION: Angiosarcomas are extremely rare tumours but should be considered as a differential diagnosis for an evolving mass near the site of an AV fistula. Diagnosis relies on an index of suspicion and obtaining a definitive histological diagnosis. Both clinicians and patients should be aware that an evolving mass within or around an AV fistula should prompt urgent biopsy.
No takes yet. Share an insight, caveat, or question.
Qureshi et al. (2010) conducted a case report in Angiosarcoma in a ligated native AV fistula post-renal transplant (n=1). Immunosuppression post-renal transplant was evaluated on Development of angiosarcoma. A 48-year-old male developed an extremely rare angiosarcoma in a ligated native arteriovenous fistula on the background of immunosuppression following a renal transplant.
Synapse has enriched 10 related papers. Consider them for comparative context: